

Adenosine Triphosphate (ATP)-Stabilized Gold Nanoparticle Based-colorimetric Acetylcholinesterase Assay Method with High Signal/Noise Ratio in End-point Analysis

Min Sik Eom, Sudeok Kim, Sujung Yi, Seok Keun Choi,[†] and Min Su Han*

Department of Chemistry, Chung-Ang University, Seoul 156-756, Korea. *E-mail: mshan@cau.ac.kr

[†]Department of Civil Engineering, Chungbuk National University, Cheongju-si, Chungbuk 361-763, Korea

Received September 30, 2010, Accepted October 26, 2010


Key Words: Adenosine triphosphate, Gold nanoparticle, Assay, Acetylcholinesterase

Alzheimer's disease is a highly prevalent neurodegenerative disease that is characterized initially by the selective loss of cholinergic neurons in the basal forebrain. The loss of cholinergic cells, particularly in the basal forebrain, is accompanied by the loss of the neurotransmitter, acetylcholine.¹ Acetylcholinesterase inhibitors form the basis of the newest drugs available for the management of this disease because this enzyme rapidly hydrolyzes the active neurotransmitter acetylcholine into inactive compounds, choline and acetic acid.² These inhibitors can treat Alzheimer's disease by increasing the level of acetylcholine by blocking the activity of acetylcholinesterase. Many compounds have been synthesized by combinatorial chemistry to discover acetylcholinesterase inhibitors rapidly.³ Combinatorial chemistry enables to large libraries of compounds to be synthesized within a short time period, and the libraries of compounds have enabled the development of many potential acetylcholinesterase inhibitors as drugs for Alzheimer's disease.^{3,4} However, one of the bottlenecks in drug discovery is the selection of drug candidates from the many compounds in these libraries.⁵ To overcome this problem, high-throughput screening methods were used to screen large libraries of potential drug candidates.⁶ Previously, many high throughput screening compatible methods for acetylcholinesterase have been developed based on fluorescent dyes, chromogenic dyes, gold nanoparticles, silver nanoparticles, polymer, mass spectroscopy, high performance chromatography and thin layer chromatography.⁷ Among these methods, the most common is an organic dye based-method that involves the activation of an enzyme cascade, where acetylcholinesterase hydrolyses acetylthiocholine to thiocholine. The subsequent product produces a colorimetric product by reacting with thiol reactive chromogenic dyes, such as 5,5'-dithio-bis(2-nitrobenzoic acid) (DTNB or Ellman's reagent).⁸ Although the colorimetric method is used widely, the method suffers from low sensitivity, low signal/noise ratio and high background absorbance when used as a high throughput screen for a large size library.⁷ⁱ As a result, other colorimetric high throughput screening methods of a library of acetylcholinesterase inhibitors are needed.

Gold nanoparticles (AuNPs) can be a good thiol reactive-chromogenic dye for a thioester-based enzyme assay, such as acetylcholinesterase, because they have 3 - 5 orders of magnitude higher extinction coefficients than organic dye molecules.⁹ Moreover, when AuNPs are exposed to thiol, they aggregate immediately to induce a dramatic red to blue color change.⁹

However, unmodified AuNPs, such as citric acid-capped AuNPs, are difficult to use in the real-time monitoring of the activity of the target enzyme because the AuNPs are quite sensitive to a range of factors, such as the electrolyte concentration, pH of the buffer and protein concentration.⁹ Therefore, a change in any of the abovementioned parameters results in irreversible aggregation of unmodified AuNPs as well as a significant red shift in the absorbance spectrum. Therefore, unmodified AuNPs are difficult to use for the real-time monitoring of the activity of the target enzyme. To solve these problems, the properties of ATP-stabilized gold nanoparticles (sAuNPs) were recently employed for the real-time monitoring of the activity of protease.¹⁰ The sAuNPs are stable in a buffer solution in the presence of high salt concentrations. However, the color of the sAuNPs solution changes immediately when exposed to the thiol produced by the target enzyme, which hydrolyzes the thioester bond on the substrate. In this paper, the strategy of the enzyme assay method was expanded to assay the activities of acetylcholinesterase and its inhibitors.

In this assay, sAuNPs and acetylthiocholine (**1**) were used. The thioester bond can be cleaved catalytically using acetylcholinesterase, and the hydrolyzed product (thiocholine) can react with sAuNPs. This process causes a change in the optical properties of the sAuNPs, and an assay of the enzyme activity becomes possible as Scheme 1. Firstly, the stability of the AuNPs stabilized with various concentrations of ATP was tested in the presence of **1** because the stability of sAuNPs to a thioester is quite sensitive to the ATP concentration. The sAuNPs are stable to acetylthiocholine in the case of AuNPs stabilized with higher concentrations of 10 μ M ATP (see supplemental infor-



Scheme 1. Schematic diagram of the colorimetric acetylcholinesterase assay




Figure 1. (a) Monitoring of the acetylcholinesterase-catalyzed hydrolysis of acetylthiocholine (20 μ M) to thiocholine at pH 7.0 (10 mM SPB + 10 mM NaCl) using the ATP stabilized AuNPs (3 nM). Hydrolysis was monitored at an extinction wavelength of 680 nm. (b) Replot of T_{a50} against the acetylcholinesterase concentrations (0, 6.0, 7.5, 10.0, 12.5, 15.0, 17.5, and 20.0 mU/mL).

mation). Therefore, the AuNPs stabilized by mixing ATP (20 μ M) with AuNPs (diameter: 13 nm) combined with acetylthiocholine were utilized in this assay. A mixture of sAuNPs and **1** was used to evaluate the enzymatic activity of acetylcholinesterase. As acetylcholinesterase hydrolyzes **1**, the sAuNPs are aggregated, generating a blue color due to the sAuNPs reacting with the hydrolyzed product (thiocholine). The color can be observed by the naked eye, or the absorbance (680 nm) can be measured by UV-vis spectroscopy. In a typical experiment, known concentrations of acetylcholinesterase were added to the assay mixture containing sAuNPs and **1** (10 μ M) in a pH 7.0 buffer solution (10 mM sodium phosphate buffer (SPB) + 10 mM NaCl). Upon hydrolysis of the thioester in **1** by acetylcholinesterase, the color of the sAuNPs solution changed dramatically from red to blue at a specific time. By measuring the absorbance of the solution at 680 nm (Figure 1), quantitative analysis of the acetylcholinesterase-catalyzed hydrolysis of **1** was carried out, and the reaction rate increased with increasing enzyme concentration. The kinetics of this assay showed unusual behavior in that the absorbance of the solution changed dramatically at a specific time, which may be due to the aggregation of sAuNPs when the surface of the AuNPs are modified




Figure 2. Determination of the relative activity of the acetylcholinesterase inhibitors. Plot of the UV absorbance at 680 nm as a function of time. The increase in T_{a50} was caused by the addition of an acetylcholinesterase inhibitor (20 nM) to the pH 7.0 buffer solution (10 mM SPB + 10 mM NaCl; ATP 20 μ M) containing acetylthiocholine (**1**) (20 μ M), acetylcholinesterase (20 mU/mL), and ATP stabilized AuNPs (3 nM).

with thiocholine beyond a certain point. Therefore, unlike a thiol reactive organic dye based-acetylcholinesterase assays, the kinetic parameters in an acetylcholinesterase assay and its inhibitor assay, such as IC_{50} and K_{cat} , could not be analyzed using this assay. Although this assay could not analyze the kinetic parameters, this method can have several advantages in screening a large size library compared to previous colorimetric acetylcholinesterase assays, such as the widely used Ellman reagent based-assay. This method is more sensitive than the Ellman reagent based assay.¹¹ A high throughput assay (HTS) format based on the UV-vis detection of Ellman reagent is problematic for HTS because the screening libraries often contain compounds that absorb strongly at 412 nm. However, this method can be free of these problems because it monitors the activity of acetylcholinesterase by measuring the absorbance of sAuNPs at 680 nm. In particular, because the absorbance of the assay solution changed dramatically at a specific time (Figure 1a), the unusual kinetic behavior in this assay enhances the signal/noise ratio when a large size library of acetylcholinesterase inhibitors is screened using the end-point method.

To demonstrate the advantage of this assay, the proposed assay was used to evaluate the relative activity of the acetylcholinesterase inhibitors. In a typical assay, acetylcholinesterase was added to a control solution and to the assay solutions containing one of the following acetylcholinesterase inhibitors: tarcrine, and pyridostigmine.¹² The inhibitor activity was monitored at 680 nm as a function of time (sample scan rate: 30 s^{-1}). As shown in Figure 2, the absorbance changed over a very narrow time range, and the time at which the absorbance of the assay solution shows a 50% change (T_{a50}) can be used as a parameter of inhibition. The inhibitors decrease the acetylcholinesterase activity, and increase the T_{a50} , and hence, the corresponding time required for a solution color change. The inhibitors studied exhibited the following trend in the T_{a50} values: tarcrine > pyridostigmine > control (Figure 2). This order is consistent with the activities of the inhibitors to acetylcholinesterase re-

ported in the literature.¹² In particular, at a specific time, sharp absorbance changes enable the selection of clearly more potent inhibitors than a specific inhibitor in a library. For example, at 400 seconds, compared to the absorbance of the assay solution containing pyridostigmine, the absorbance of the control assay solutions and the solution containing tacrine was > 0.2 and < 0.15 , respectively. Therefore, tacrine was found to be a more potent inhibitor than pyridostigmine by measuring the off/on signals at a specific time. The property in this assay can be very useful for end-point analysis.

In conclusion, a new colorimetric assay for screening the acetylcholinesterase activity and for determining the relative inhibitory activity of the acetylcholinesterase inhibitors was developed using a mixture of **1** and sAuNPs. This method is more sensitive than the widely used Ellman reagent based-colorimetric assay. In particular, with this screening method, a dramatic color change occurs over a very narrow time range, which enables the activities of acetylcholinesterase inhibitors to be discriminated easily with high signal/noise ratios in an end-point assay.

Experimental Section

Chemicals. All chemicals used were of analytical grade or of the highest purity available. Chloroauric acid ($\text{HAuCl}_4 \cdot 3\text{H}_2\text{O}$), citric acid, tacrine, pyridostigmine, and acetylcholinesterase (from *Electrophorus electricus*) were purchased from Sigma Aldrich (USA). All glassware was cleaned thoroughly with freshly prepared aqua regia (3:1 (v/v) HCl/HNO_3) and rinsed thoroughly with Milli-Q water prior to use. Milli-Q water was used to prepare all the solutions in this study.

Preparation of AuNPs. All glassware was washed with freshly prepared aqua regia (3:1 = $\text{HCl}:\text{HNO}_3$) followed by extensive rinsing with doubly distilled H_2O . Citric acid stabilized Au particles with a diameter of 13 nm were prepared by adding 50 mL of a citrate solution (38.8 mM) to 500 mL of boiling 1.0 mM $\text{HAuCl}_4 \cdot 3\text{H}_2\text{O}$ with vigorous stirring. After the appearance of a deep red color, boiling and stirring were continued for 15 min.

Colorimetric Screening Assay. AuNPs (diameter: 13 nm; 3 nM) were mixed with ATP (20 μM) and stabilized by incubation in distilled water. After incubation for 5 min, the concentration of the mixture was adjusted using 10 mM sodium phosphate buffer (pH 7.0, 10 mM NaCl) and acetylthiocholine (20 μM) so that the final concentration of the AuNPs and ATP were 3 nM and 20 μM , respectively. The assay was initiated by adding acetylcholinesterase from *Electrophorus electricus* (20 mU/mL) to the assay mixture, and the hydrolysis kinetics were monitored by UV-vis spectroscopy at the extinction wavelength of 680 nm. The solution was continuously stirred at room temperature with a magnetic stir bar to ensure homogeneity.

Acknowledgments. This study was supported by National Research Foundation of Korea Grant funded by the Korean Government (2009-0071807) and Priority Research Centers Program through the National Research Foundation of Korea

(NRF) funded by the Ministry of Education, Science and Technology (2009-0093817).

References and Notes

- Whitehouse, P. J.; Price, D. L.; Struble, R. G.; Clark, A. W.; Coyle, J. T.; DeLong, M. R. *Science* **1982**, *215*, 1237-1239.
- (a) Francotte, P.; Graindorge, E.; Boverie, S.; de Tullio, P.; Piroette, B. *Curr. Med. Chem.* **2004**, *11*, 1757-1778. (b) Ibach, B.; Haen, E. *Curr. Pharm. Des.* **2004**, *10*, 231-251. (c) Parihar, M. S.; Hemmani, T. *J. Clin. Neurosci.* **2004**, *11*, 456-467.
- (a) Ansari, F. L.; Iftikhar, F.; Ihsan-Ul-Haq; Mirza, B.; Baseer, M.; Rashid, U. *Bioorg. Med. Chem.* **2008**, *16*, 7691-7697. (b) Bunyapaiboonsri, T.; Ramström, O.; Lohmann, S.; Lehn, J.-M.; Peng, L.; Goeldner, M. *ChemBioChem* **2001**, *2*, 438-444. (c) Mulcahy, S. P.; Li, S.; Korn, R.; Xie, X.; Meggers, E. *Inorg. Chem.* **2008**, *47*, 5030-5032. (d) Krasinski, A.; Radić, Z.; Manetsch, R.; Raushel, J.; Taylor, P.; Sharpless, K. B.; Kolb, H. C. *J. Am. Chem. Soc.* **2005**, *127*, 6686-6692. (e) Recanatini, M.; Cavalli, A.; Belluti, F.; Piazzi, L.; Rampa, A.; Bisi, A.; Gobbi, S.; Valentini, P.; Andrisano, V.; Bartolini, M.; Cavrini, V. *J. Med. Chem.* **2000**, *43*, 2007-2018. (f) Kapková, P.; Heller, E.; Unger, M.; Folkers, G.; Holzgrabe, U. *J. Med. Chem.* **2005**, *48*, 7496-7499. (g) Fallarero, A.; Oinonen, P.; Gupta, S.; Blom, P.; Galkin, A.; Mohan, C. G.; Vuorela, P. M. *Pharmacol. Res.* **2008**, *58*, 215-221. (h) Scheck, M.; Koch, M. A.; Waldmann, H. *Tetrahedron* **2008**, *64*, 4792-4802.
- (a) Thompson, L. A.; Ellman, J. A. *Chem. Rev.* **1996**, *96*, 555-600. (b) Balkenhohl, F.; von dem Bussche-Hünnefeld, C.; Lansky, A.; Zechel, C. *Angew. Chem. Int. Ed. Engl.* **1996**, *35*, 2288-2337.
- Walker, M. J. A.; Barrett, T.; Guppy, L. J. *Drug Discov. Today: Targets* **2004**, *3*, 208-215.
- (a) Johnston, P. A.; Johnston, P. A. *Drug Discov. Today* **2002**, *7*, 353-363. (b) Boger, D. L.; Desharnais, J.; Capps, K. *Angew. Chem. Int. Ed.* **2003**, *42*, 4138-4176. (c) Wang, S.; Sim, T. B.; Kim, Y.-S.; Chang, Y.-T. *Curr. Opin. Chem. Biol.* **2004**, *8*, 371-377.
- (a) Maeda, H.; Matsuno, H.; Ushida, M.; Katayama, K.; Saeki, K.; Itoh, N. *Angew. Chem. Int. Ed.* **2005**, *44*, 2922-2925. (b) Wang, M.; Gu, X.; Zhang, G.; Zhang, D.; Zhu, D. *Anal. Chem.* **2009**, *81*, 4444-4449. (c) Zhu, J.; Dhimitruka, I.; Pei, D. *Org. Lett.* **2004**, *6*, 3809-3812. (d) Grasseti, D. R.; Murray, J. F., Jr. *Arch. Biochem. Biophys.* **1967**, *119*, 41-49. (e) Wang, M.; Gu, X.; Zhang, G.; Zhang, D.; Zhu, D. *Langmuir* **2009**, *25*, 2504-2507. (f) Pavlov, V.; Xiao, Y.; Willner, I. *Nano Lett.* **2005**, *5*, 649-653. (g) Virel, A.; Saa, L.; Pavlov, V. *Anal. Chem.* **2009**, *81*, 268-272. (h) Feng, F.; Tang, Y.; Wang, S.; Li, Y.; Zhu, D. *Angew. Chem. Int. Ed.* **2007**, *46*, 7882-7886. (i) Xu, Z.; Yao, S.; Wei, Y.; Zhou, J.; Zhang, L.; Wang, C.; Guo, Y. *J. Am. Soc. Mass Spectrom.* **2008**, *19*, 1849-1855. (j) de Jong, C. F.; Derks, R. J. E.; Bruyneel, B.; Niessen, W.; Irth, H. *J. Chromatogr. A* **2006**, *1112*, 303-310. (k) Zheng, X.-Y.; Zhang, Z.-J.; Chou, G.-X.; Wu, T.; Cheng, X.-M.; Wang, C.-H.; Wang, Z.-T. *Arch. Pharm. Res.* **2009**, *32*, 1245-1251.
- Ellman, G. L.; Courtney, K. D.; Andres, V., Jr.; Feather-Stone, R. M. *Biochem. Pharmacol.* **1961**, *7*, 88-95.
- (a) Stewart, M. E.; Anderton, C. R.; Thompson, L. B.; Maria, J.; Gray, S. K.; Rogers, J. A.; Nuzzo, R. G. *Chem. Rev.* **2008**, *108*, 494-521. (b) Ghosh, S. K.; Pal, T. *Chem. Rev.* **2007**, *107*, 4797-4862. (c) Burda, C.; Chen, X.; Narayanan, R.; El-Sayed, M. A. *Chem. Rev.* **2005**, *105*, 1025-1102. (d) Rosi, N. L.; Mirkin, C. A. *Chem. Rev.* **2005**, *105*, 1547-1562.
- Kim, M. H.; Lee, S. S.; Chung, S. J.; Jang, H. H.; Yi, S.; Kim, S.; Chang, S.-K.; Han, M. S. *Tetrahedron Lett.* **2010**, *51*, 2228-2231.
- Rhee, K.; van de Meent, M.; Ingkaninan, K.; Verpoorte, R. *J. Chromatogr. A* **2001**, *915*, 217-223.
- Arnal, F.; Coté, L. J.; Ginsburg, S.; Lawrence, G. D.; Naini, A.; Sano, M. *Neurochem. Res.* **1990**, *15*, 587-591. Ling, R.; Yoshida, M.; Mariano, P. S. *J. Org. Chem.* **1996**, *61*, 4439-4449.